|
|
|
|
1 Historical Perspective of Scleroderma |
|
|
3 | (8) |
|
|
|
|
|
Part II Epidemiology, Genetics and Classification |
|
|
|
2 Epidemiology, Environmental, and Infectious Risk Factors |
|
|
11 | (14) |
|
|
|
|
|
|
|
|
|
25 | (14) |
|
|
|
|
|
4 Disease Subsets in Clinical Practice |
|
|
39 | (10) |
|
|
|
|
|
5 Evolving Concepts of Diagnosis and Classification |
|
|
49 | (16) |
|
|
|
|
|
|
|
Frank H.J. Van den Hoogen |
|
|
|
|
65 | (10) |
|
|
|
|
|
7 Juvenile Localized and Systemic Scleroderma |
|
|
75 | (16) |
|
|
|
|
|
|
|
8 Morphea (Localized Scleroderma) |
|
|
91 | (24) |
|
|
|
|
|
|
|
115 | (10) |
|
|
|
|
|
10 Systems Biology Approaches to Understanding the Pathogenesis of Systemic Sclerosis |
|
|
125 | (8) |
|
|
|
|
|
|
|
Part III The Biological Basis of Systemic Sclerosis |
|
|
|
11 Introduction: The Etiopathogenesis of Systemic Sclerosis - An Integrated Overview |
|
|
133 | (8) |
|
|
|
|
|
12 Pathology of Systemic Sclerosis |
|
|
141 | (20) |
|
|
|
|
|
13 Inflammation and Immunity |
|
|
161 | (36) |
|
|
|
|
|
14 Autoantibodies as Markers and Possible Mediators of Scleroderma Pathogenesis |
|
|
197 | (10) |
|
|
|
|
|
15 The Clinical Aspects of Autoantibodies |
|
|
207 | (14) |
|
|
|
|
|
16 Mechanisms of Vascular Disease |
|
|
221 | (24) |
|
|
|
|
|
17 Biomarkers in Systemic Sclerosis |
|
|
245 | (16) |
|
|
|
|
|
18 Pathophysiology of Fibrosis in Systemic Sclerosis |
|
|
261 | (20) |
|
|
|
|
|
19 Overview of Animal Models |
|
|
281 | (16) |
|
|
|
|
|
Part IV Cardiovascular Manifestations and Management |
|
|
|
20 Raynaud's Phenomenon, Digital Ulcers and Nailfold Capillaroscopy |
|
|
297 | (20) |
|
|
|
|
|
|
|
21 Renal Crisis and Other Renal Manifestations of Scleroderma |
|
|
317 | (14) |
|
|
|
|
|
22 Cardiac Involvement: Evaluation and Management |
|
|
331 | (28) |
|
|
|
|
|
|
|
Part V Pulmonary Manifestations and Management |
|
|
|
23 Overview of Lung Involvement: Diagnosis, Differential Diagnosis and Monitoring |
|
|
359 | (4) |
|
|
|
24 Clinical Assessment of Lung Disease |
|
|
363 | (12) |
|
|
|
|
|
|
|
25 Treatment of Interstitial Lung Disease |
|
|
375 | (10) |
|
|
|
|
|
26 Pathogenesis of Pulmonary Arterial Hypertension |
|
|
385 | (18) |
|
|
|
|
|
|
|
27 Clinical Assessment of Pulmonary Hypertension |
|
|
403 | (8) |
|
|
|
|
|
28 The Management of Pulmonary Arterial Hypertension in the Setting of Systemic Sclerosis |
|
|
411 | (12) |
|
|
|
|
|
Part VI Gastrointestinal Manifestations and Management |
|
|
|
29 Overview of Gastrointestinal Tract Involvement |
|
|
423 | (4) |
|
|
|
30 Upper Gastrointestinal Tract: Manifestations of Systemic Sclerosis |
|
|
427 | (16) |
|
|
|
|
|
31 Small and Large Intestinal Involvement and Nutritional Issues |
|
|
443 | (18) |
|
|
|
|
|
|
|
Part VII Skin, Musculoskeletal and Other Complications |
|
|
|
|
|
461 | (12) |
|
|
|
|
|
33 Evaluation and Management of Skin Disease |
|
|
473 | (16) |
|
|
|
|
|
34 Assessment and Management of Progressive Skin Involvement in Diffuse Scleroderma |
|
|
489 | (10) |
|
|
|
35 Skeletal Muscle Involvement |
|
|
499 | (8) |
|
|
|
36 Tendons, Joints, and Bone |
|
|
507 | (18) |
|
|
|
|
|
|
|
37 Cancer in Systemic Sclerosis |
|
|
525 | (8) |
|
|
|
|
|
38 Overlooked Manifestations |
|
|
533 | (18) |
|
|
|
|
|
|
|
|
|
551 | (14) |
|
|
|
|
|
Part VIII Management and Outcome Assessment |
|
|
|
40 Introduction to Section VIII: Management and Outcome Assessment |
|
|
565 | (2) |
|
|
|
|
|
|
|
41 Immunomodulatory, Immunoablative, and Biologic Therapies |
|
|
567 | (16) |
|
|
|
|
|
42 Investigative Approaches to Drug Therapy |
|
|
583 | (12) |
|
|
|
|
|
43 Drug Development and Regulatory Considerations for SSc Therapies |
|
|
595 | (8) |
|
|
|
44 Physical and Occupational Therapy |
|
|
603 | (12) |
|
|
|
|
|
45 Psychosocial Issues and Care for Patients with Systemic Sclerosis |
|
|
615 | (8) |
|
|
|
|
|
|
|
|
|
|
|
46 Clinical Trial Design in Systemic Sclerosis |
|
|
623 | (14) |
|
|
|
|
|
|
|
47 Measuring Disease Activity and Outcomes in Clinical Trials |
|
|
637 | (12) |
|
|
|
|
|
48 Innovative Approaches to Clinical Trials in Systemic Sclerosis |
|
|
649 | (8) |
|
|
|
|
|
|
|
49 Molecular Stratification by Gene Expression as a Paradigm for Precision Medicine in Systemic Sclerosis |
|
|
657 | (16) |
|
|
|
|
|
Part IX Case Studies: Approach to Complex Clinical Problems |
|
|
|
50 Managing the Ischemic Finger in Scleroderma |
|
|
673 | (6) |
|
|
|
51 Scleroderma Renal Crisis |
|
|
679 | (4) |
|
|
|
|
|
52 Rapid Diffuse Skin Disease with Progressive Joint Contractures |
|
|
683 | (8) |
|
|
|
|
|
53 Management of the Scleroderma Patient with Pulmonary Arterial Hypertension Failing Initial Therapy |
|
|
691 | (10) |
|
|
|
|
|
54 Pseudo-obstruction with Malabsorption and Malnutrition |
|
|
701 | (6) |
|
|
|
55 Progressive Interstitial Lung Disease Nonresponse to Cyclophosphamide |
|
|
707 | (6) |
|
|
|
|
|
|
|
56 Coping with the Disfigurement of Scleroderma: Facial, Skin, and Hand Changes |
|
|
713 | (10) |
|
|
|
|
|
|
|
|
|
|
|
|
|
57 Managing Complicated Digital Ulcers |
|
|
723 | (8) |
|
|
| Index |
|
731 | |
